Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Endocrinology-Diabetes-Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden.
Eur J Endocrinol. 2020 Jul;183(1):R1-R11. doi: 10.1530/EJE-20-0052.
Concurrent type 1 diabetes (T1D) and Addison's disease (AD) is a rare combination of diseases and, in approximately one third of these patients, it is also combined with an autoimmune thyroid disease. Recently, it was shown that patients with both T1D and AD have a higher risk of premature death compared to patients with T1D alone, the most common causes of death being due to diabetic complications and cardiovascular disease. These patients receiving replacement therapies with both insulin and glucocorticoids face an increased risk of hypo- and hyperglycemia and diabetic ketoacidosis and have a higher risk of adrenal crisis than patients with AD alone. Treatment challenges include the opposing effects of insulin and glucocorticoids on glucose homeostasis and the need to balance and synchronize these two treatments. The rarity of this disease combination may explain the paucity of data on outcome and specific treatment strategies in this patient group. Based on this review, we suggest management strategies for their insulin and glucocorticoid replacement therapies and indicate future areas of research.
1 型糖尿病(T1D)和艾迪生病(AD)同时发生较为罕见,大约三分之一的此类患者还合并自身免疫性甲状腺疾病。最近发现,与单纯 T1D 患者相比,同时患有 T1D 和 AD 的患者过早死亡的风险更高,最常见的死亡原因是糖尿病并发症和心血管疾病。这些同时接受胰岛素和糖皮质激素替代治疗的患者发生低血糖和高血糖以及糖尿病酮症酸中毒的风险增加,且发生肾上腺危象的风险高于单纯 AD 患者。治疗面临的挑战包括胰岛素和糖皮质激素对血糖稳态的相反作用,以及平衡和同步这两种治疗方法的需求。这种疾病组合的罕见性可能解释了该患者群体的结局和特定治疗策略数据的缺乏。基于这篇综述,我们提出了他们胰岛素和糖皮质激素替代疗法的管理策略,并指出了未来的研究领域。